MRNA Jan 2024 290.000 put
| Previous close | 166.66 |
| Open | 167.23 |
| Bid | 145.85 |
| Ask | 153.65 |
| Strike | 290.00 |
| Expiry date | 2024-01-19 |
| Day's range | 166.66 - 167.23 |
| Contract range | N/A |
| Volume | |
| Open interest | 35 |
- Motley Fool
Why Sanofi May Be a Frontrunner in Endemic COVID-19
Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.
- Motley Fool
If You Invested $10,000 in Moderna 2 Years Ago, This Is How Much You Would Have Today
Moderna (NASDAQ: MRNA) was one of the best stocks to own last year as it brought its COVID-19 vaccine to market and generated billions in revenue. The company, which was a bit of an unknown before the pandemic began, has quickly risen in popularity.
- Motley Fool
1 Green Flag for Moderna's Fall Vaccine Plan, and 1 Red Flag
Moderna (NASDAQ: MRNA) took center stage when it launched its coronavirus vaccine about a year and a half ago. Moderna recently reported that its booster candidate offers "superior" performance against the omicron variant.
